Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Idiopathic Pulmonary Fibrosis Market is projected to expand from USD 3.88 billion in 2025 to USD 5.73 billion by 2031, reflecting a compound annual growth rate of 6.71%. Therapeutics for Idiopathic Pulmonary Fibrosis (IPF) include antifibrotic drugs and adjunctive treatments aimed at slowing irreversible lung scarring and maintaining respiratory capacity. This growth is primarily driven by an aging global population, given the strong correlation between the disease and advanced age, as well as advancements in high-resolution imaging that allow for earlier and more precise diagnosis. Data from the Pulmonary Fibrosis Foundation in 2024 indicates that pulmonary fibrosis and interstitial lung diseases affect more than 250,000 Americans, with roughly 50,000 new diagnoses annually.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.88 Billion
Market Size 2031	USD 5.73 Billion
CAGR 2026-2031	6.71%
Fastest Growing Segment	Pirfenidone
Largest Market	North America

Despite these positive factors, market expansion faces a major obstacle in the form of the high cost of long-term antifibrotic treatments, which hinders patient access in healthcare systems with strict reimbursement policies. This financial hurdle, often compounded by stringent payer approval criteria, restricts the broad utilization of these life-extending therapies across both developed and emerging regions.

Market Driver

The rising prevalence of Idiopathic Pulmonary Fibrosis (IPF) acts as a key determinant of market progress, requiring a corresponding increase in therapeutic availability and patient support infrastructures. Improvements in diagnostic capabilities enable healthcare providers to detect more instances of this chronic, progressive lung condition, thereby escalating the demand for long-term management strategies. This increasing disease burden is a global health issue rather than a regional one, fueling the commercial need for effective treatments; for instance, the Canadian Pulmonary Fibrosis Foundation's 'Hope Breathes Here Press Release' in September 2024 noted that approximately 30,000 Canadians are currently living with pulmonary fibrosis, underscoring the large patient population needing care.

Concurrently, the rapid uptake of advanced antifibrotic therapies significantly boosts market value, as these medications remain the standard of care for retarding disease progression. The commercial viability of existing agents stimulates ongoing research and development, fostering a competitive landscape focused on efficacy and safety. The strong demand for pharmaceutical interventions is reflected in financial results; Boehringer Ingelheim's April 2024 'Annual Report 2023' reported net sales of 3.5 billion EUR for their fibrosis portfolio, led by Ofev. Furthermore, the market continues to attract investment for future innovations, as demonstrated by Vicore Pharma, which raised approximately 782 million SEK in a 2024 rights issue to progress its lead candidate through clinical trials.

Market Challenge

The exorbitant cost associated with long-term antifibrotic therapy represents a major economic hurdle slowing the growth of the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Although these medications effectively retard disease progression, their high prices often surpass the financial capacity of both patients and healthcare systems. As a result, insurance providers and payers frequently enforce rigorous reimbursement standards, such as necessitating proof of lung function decline prior to approval, which delays the start of treatment and shrinks the eligible patient pool, ultimately lowering revenue potential.

This financial toxicity not only hinders new patient enrollment but also leads to high rates of treatment abandonment. Patients confronted with significant out-of-pocket costs are often compelled to prioritize essential living expenses over medication adherence, resulting in poorer clinical outcomes and decreased drug sales volume. Highlighting this burden, the Pulmonary Fibrosis Foundation noted in 2024 that Medicare beneficiaries in the United States faced an annual out-of-pocket spending cap of roughly $8,000 for prescription drugs before new limits were enacted, demonstrating the severe economic strain on the elderly population most susceptible to the disease. These economic pressures create a restrictive atmosphere that suppresses the widespread uptake of therapeutics, thereby impeding overall market expansion.

Market Trends

The integration of Artificial Intelligence into diagnostic imaging is transforming the Global Idiopathic Pulmonary Fibrosis Market by substituting subjective manual evaluations with automated, quantitative biomarkers that more accurately predict disease progression. These AI-powered tools examine computed tomography scans to measure variations in lung structure, equipping clinicians with reliable data for patient stratification in clinical trials and personalized care. According to a March 2025 report by the National Institutes of Health on highlights from the 'ERS Congress 2024', the AI-derived Weighted Reticulovascular Score (WRVS) showed superior prognostic ability over traditional densitometry, identifying patients with a high mortality risk through a hazard ratio of 4.55.

Additionally, the rise of Next-Generation Mechanism-Specific Therapies marks a critical transition from broad-spectrum antifibrotics to precision agents that target specific pathogenic pathways, such as lysophosphatidic acid signaling. This trend is motivated by the critical need to enhance patient adherence and results via drugs that provide improved safety profiles and targeted efficacy compared to legacy treatments like pirfenidone and nintedanib. As reported by Chest Physician in July 2025 regarding the article 'Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis', the investigational LPA1 antagonist admilparant resulted in a 54% relative risk reduction in lung function decline among idiopathic pulmonary fibrosis patients treated with the 60 mg dose.

Key Market Players

Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
Cipla Limited
Shionogi & Co., Ltd
Bristol-Myers Squibb Company
United Therapeutics Corporation
FibroGen, Inc
Pliant Therapeutics, Inc
Galecto, Inc.
CSL Behring

Report Scope

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Idiopathic Pulmonary Fibrosis Market, By Drug Type

Pirfenidone
Nintedanib
others

Idiopathic Pulmonary Fibrosis Market, By Route of Administration

Parenteral
Oral
Others

Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Idiopathic Pulmonary Fibrosis Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

Global Idiopathic Pulmonary Fibrosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Idiopathic Pulmonary Fibrosis Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Pirfenidone, Nintedanib, others)
- 5.2.2. By Route of Administration (Parenteral, Oral, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Idiopathic Pulmonary Fibrosis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Idiopathic Pulmonary Fibrosis Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Idiopathic Pulmonary Fibrosis Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Idiopathic Pulmonary Fibrosis Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Distribution Channel

7. Europe Idiopathic Pulmonary Fibrosis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Idiopathic Pulmonary Fibrosis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Idiopathic Pulmonary Fibrosis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Idiopathic Pulmonary Fibrosis Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Idiopathic Pulmonary Fibrosis Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Idiopathic Pulmonary Fibrosis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Idiopathic Pulmonary Fibrosis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Idiopathic Pulmonary Fibrosis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Idiopathic Pulmonary Fibrosis Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Idiopathic Pulmonary Fibrosis Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. UAE Idiopathic Pulmonary Fibrosis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. South Africa Idiopathic Pulmonary Fibrosis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Distribution Channel

10. South America Idiopathic Pulmonary Fibrosis Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Idiopathic Pulmonary Fibrosis Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Colombia Idiopathic Pulmonary Fibrosis Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Argentina Idiopathic Pulmonary Fibrosis Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Idiopathic Pulmonary Fibrosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Boehringer Ingelheim International GmbH
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Cipla Limited
15.4. Shionogi & Co., Ltd
15.5. Bristol-Myers Squibb Company
15.6. United Therapeutics Corporation
15.7. FibroGen, Inc
15.8. Pliant Therapeutics, Inc
15.9. Galecto, Inc.
15.10. CSL Behring